& Seim, H
Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Most Doubt the Trump Administration Will Lower Drug Costs for People Like Them, Though Three-Fourths of Republicans Expect It Will About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds
Diabetes Obes Metab 12:532539 Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T (2013) A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Reconstitution: For laboratory research applications, qualified personnel must reconstitute this material under aseptic conditions
Whether its deciding between Ozempic and Mounjaro for their dosing frequency and efficacy in managing Type 2 diabetes or comparing Wegovy and Zepbound for their main FDA-approved use in weight loss, patients and healthcare providers now have a comprehensive guide to navigate these decisions
Treatment should be discontinued if patients do not achieve at least 5% weight loss after 6 months (semaglutide) or 12 weeks (liraglutide)